Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Eli Lilly and Company

LLY ✓ COMPLIANT ☆ Track — members

NYSE · Healthcare · Pharmaceuticals ·

USA Mega Cap Analyst: BUY

Last Close

$1,115.70

▼ -0.65%

Market Cap $1.05T · Vol 604.79K

Key Metrics

P/E Ratio

37.44

FWD: 25.24

Market Cap

$1.05T

Mega Cap

Div Yield

0.62%

Quarterly dividend

EPS Growth

+52.28%

YoY

RSI (14)

2.48

Momentum

Beta

0.46

vs Market

52W High

$1,292.60

13.69% below

52W Low

$712.13

56.67% above

Volume

604.79K

Avg 711.73K

P/B

38.26

Price-to-book

ROE

106.90%

Return on equity

Free Float

99.78%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Eli Lilly and Company (LLY) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LLY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.79%

-8.17%

-3.90%

+11.59%

YTD

+3.82%

+47.52%

+86.17%

+365.85%

Financials & Valuation

TTM · Annual

Total Revenue	$65.18B
Net Income	$20.64B
Revenue Growth (YoY)	+47.67%
Gross Margin	83.04%
Operating Margin	45.56%
Net Profit Margin	31.67%
ROE	106.90%
ROA · ROIC	26.92% · 36.52%

P/E Ratio	37.44
Forward P/E (FY1)	25.24
PEG Ratio	0.49
P/S	14.83
P/B	38.26
P/FCF	162.05
EPS Growth	+52.28%
Outstanding Shares	941.36M

Technical Indicators

50-Day SMA	$1,184.65
200-Day SMA	$1,064.85
RSI (14)	2.48
Beta	0.46
52-Week High	$1,292.60
52-Week Low	$712.13

Volume Today	604.79K
Avg Daily Volume (30D)	711.73K
Relative Volume	0.85x
Volatility (10D)	12.15
Volatility (30D)	31.76
Free Float	99.78%

Analyst Consensus

BUY

Current Price $1,115.70

Mean Target $1,300.31

52W Low$712.13 52W High$1,292.60

Current

Target

$712.13 $1,292.60

Current Analyst target

+16.55% upside potential · 33 analysts

Identifiers

ExchangeNYSE

FIGIBBG001S5STL8

ISINUS5324571083

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 29, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

JNJ Johnson & Johnson -0.29% ABBV AbbVie Inc. +0.83% NVS Novartis AG -0.23% NOVN.S Novartis AG -0.09% AZN AstraZeneca PLC +0.33%

Company Profile

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.